预约演示
更新于：2025-02-15
Diclofenac Sodium
双氯芬酸钠
更新于：2025-02-15
概要
基本信息
简介双氯酚酸钠是苯乙酸衍生物，是一种非甾体抗炎药（NSAID），具有镇痛、抗炎和解热作用。和其他NSAIDs一样，双氯酚酸钠的作用机制尚未完全理解，但涉及抑制环氧化酶（COX-1和COX-2）。FDA于1988年7月28日批准双氯酚酸钠（VOLTAREN ）上市，其原产公司为Ciba-Geigy公司，现已并入诺华。这种药物已经长期用于管理多种疼痛症状，并且有处方和非处方制剂 |
药物类型 小分子化药 |
别名 Diclfenac Sodium、Diclofanac Sodium、DICLOFENAC + [119] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H11Cl2NNaO2 |
InChIKeyVSFBPYWDRANDLM-UHFFFAOYSA-N |
CAS号15307-79-6 |
关联
340
项与 双氯芬酸钠 相关的临床试验CTRI/2024/11/076121
A Randomized Controlled Clinical Trial for Vednasthapan (Analgesic) Effect of Ashoka (Saraca asoca) Ghan Vati in Comparison with Diclofenac Sodium in Post-operative Pain. - NIL
ChiCTR2500095734
The study on the effect of sodium diclofenac suppositories for postoperative analgesia after repeat cesarean section.
NCT06693648
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 in the Treatment of Pain and Symptoms of Knee Osteoarthritis
100 项与 双氯芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸钠 相关的专利（医药）
登录后查看更多信息
23,994
项与 双氯芬酸钠 相关的文献（医药）2025-06-01SEPARATION AND PURIFICATION TECHNOLOGY
Strong enhancement on diclofenac degradation in Cu(II)/H2O2 system by adding ascorbic acid: Efficiency, mechanism and influencing factors
作者: Zou, Jing ; Li, Fei ; Yang, Zhimin ; Chen, Lingxin ; Qiu, Shiyi ; Wu, Jianying ; Zhou, Zhenming ; Liu, Shupo ; Cai, Yajuan
Utilization of trace Cu(II) (at μM level) inherently existing in wastewater to activate hydrogen peroxide (H2O2) has exhibited significant potential to remove aqueous organic contaminants.Nevertheless, the Cu(II)/H2O2 system was only efficient under alk. conditions.Herein, ascorbic acid (H2A), an environmentally benign and natural reductant, was introduced to broaden pH range of Cu(II)/H2O2 process by expediting the Cu(II)/Cu(I) cycle.The H2A/Cu(II)/H2O2 system performed well in degrading diclofenac across a wide pH range from 4.0 to 9.0, and its kinetic rate constant of diclofenac elimination was 247 times greater than its counterpart without H2A at the optimal pH of 6.0, outperforming the performance of most previously reported reductant-enhanced Cu(II)/H2O2 system.ESR anal., periodate colorimetric method, and in situ Raman spectroscopy tests indicated that hydroxyl radical (HO.), rather than Cu(III), was the dominant reactive species of diclofenac degradationThirteen degradation products of diclofenac were identified by LC-Q-TOF-MS, and five different elimination pathways were proposed.Furthermore, the presence of SO2-4 exerted an insignificant influence on diclofenac degradation, while the addition of Cl-, HCO-3 and humic acid slightly suppressed the abatement of diclofenac.H2A/Cu(II)/H2O2 system was still highly efficient in degrading diclofenac in actual water matrix (i.e., reservoir water and lake water).Overall, this study provided an eco-friendly approach to enhance the oxidation capacity of the Cu(II)/H2O2 system over a wide pH range, which might be a potential technol. for degrading refractory organic pollutants in water treatment.
2025-06-01SEPARATION AND PURIFICATION TECHNOLOGY
Unraveling the transport mechanism of trace organic compounds through loose nanofiltration membranes
作者: Mo, Jiahao ; Yang, Yang ; Li, Xianhui ; Yang, Yihui ; Cheng, Yanjun
Loose nanofiltration (LNF) membranes have demonstrated exceptional efficacy in removing trace organic pollutants (TrOCs) due to their distinctive structure and efficient solute transport characteristics.Despite significant advancements, the mechanism underlying solute transport within LNF membranes remain to be further elucidated.In this study, the Donnan-Steric Pore Model with Dielec. Exclusion (DSPM-DE) was employed to predict the selectivity and permeability of customized LNF membranes, with these theor. predictions substantiated through filtration experiments utilizing particles of diverse sizes and charges.The observations reveal that when the pore size considerably exceeds the ionic sizes, the selective transport of organic pollutants and charged ions is predominantly governed by size exclusion rather than electrostatic repulsion.Moreover, in the selective transport of neutral and charged organic pollutants, charged pollutants are preferentially intercepted via electrostatic repulsion, whereas neutral pollutants are primarily influenced by convection and diffusion processes, resulting in partial interception.In addition, the ionization degree of organic substances directly affects the contribution of elec. migration to the retention rate.These observations will provide critical insights into the key solute mass transport processes for the efficient removal of TrOCs using LNF membranes.
2025-05-01SEPARATION AND PURIFICATION TECHNOLOGY
Green room-temperature fabrication of phosphotungstic acid functionalized MOF-808 for efficient removal of cationic antibiotics
作者: Shi, Kaili ; Liu, Keke ; Su, Honghao ; Zhang, Yatao ; Zhu, Junyong
ZrIV-based metal-organic frameworks (MOFs)-featuring exceptional water stability, large surface area, and structural tunability-hold promise for efficient antibiotics adsorption from water.However, their inherent pos. charge in neutral environments and the harsh conditions required for their synthesis hinder their effective removal of cationic antibiotics.To address this challenge, a green one-pot synthesis approach was proposed to fabricate phosphotungstic acid-functionalized MOF-808 (termed as PTA@MOF-808) at room temperature for elevated antibiotic adsorption.This approach not only leverages the strong electronegativity of PTA to improve electrostatic interactions and π-π stacking but also finely tailors the pore size of MOF-808, resulting in enhanced adsorption capacity of PTA@MOF-808.The influence of PTA loading, solution pH, and absorbent dosage on the performance of PTA@MOF-808 were studied in detail.Adsorption experiments demonstrated that PTA@MOF-808 outperformed unmodified MOF-808 in removing various pos. charged antibiotics, with 5% PTA@MOF-808 exhibiting maximum adsorption capacities of 548.1 mg g-1 and 482.9 mg g-1, for DOX and TCHC, resp.The adsorption process followed the Langmuir isothermal model and the pseudo-second-order kinetic equation.Furthermore, the composite PTA@MOF-808 displayed excellent reusability after multiple adsorption-desorption cycles.These findings highlight the potential of PTA@MOF-808 as a promising absorbent for removing specific antibiotics from water, with significant implications for wastewater treatment.
100 项与 双氯芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滑囊炎 | 日本 | 2022-06-20 | |
| 颈臂综合征 | 日本 | 2022-06-20 | |
| 腰痛 | 日本 | 2022-06-20 | |
| 癌症疼痛 | 日本 | 2021-03-23 | |
| 膝关节炎 | 美国 | 2014-01-16 | |
| 骨关节炎 | 日本 | 2004-02-27 | |
| 关节周围炎 | 日本 | 2004-02-27 | |
| 肌腱病 | 日本 | 2004-02-27 | |
| 腱鞘炎 | 日本 | 2004-02-27 | |
| 光化性角化病 | 美国 | 2000-10-16 | |
| 超敏反应 | 美国 | 2000-10-16 | |
| 怀孕 | 美国 | 2000-10-16 | |
| 可见病灶 | 美国 | 2000-10-16 | |
| 术后炎症 | 日本 | 1989-03-31 | |
| 强直性脊柱炎 | 美国 | 1988-07-28 | |
| 类风湿关节炎 | 美国 | 1988-07-28 | |
| 炎症 | 日本 | 1973-08-08 | |
| 疼痛 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肌痛 | 临床3期 | 美国 | 2014-10-01 | |
| 挫伤 | 临床3期 | 德国 | 2011-01-01 | |
| 软组织损伤 | 临床3期 | 德国 | 2011-01-01 | |
| 踝损伤 | 临床3期 | 美国 | 2010-11-01 | |
| 晒伤 | 临床3期 | 法国 | 2006-11-01 | |
| 痛风性关节炎 | 临床1期 | 中国 | 2022-10-14 | |
| 发热 | 临床1期 | 中国 | 2022-10-14 | |
| 头痛 | 临床1期 | 中国 | 2022-10-14 | |
| 风湿热 | 临床1期 | 中国 | 2022-10-14 | |
| 肩痛 | 临床1期 | 中国 | 2022-10-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 437 | 鬱觸繭壓簾膚壓鑰夢艱(醖膚憲夢簾衊艱積積壓) = 5 pts experienced any grade treatment emergent adverse events (TEAEs). All TEAEs were grade 1-2. TEAE leading to treatment discontinuation was occurred in one pt. 淵蓋艱窪鑰鬱繭鹽鏇衊 (鏇窪壓觸鏇繭餘憲顧鑰 ) | 积极 | 2024-05-24 | |||
Placebo | |||||||
临床3期 | - | 264 | Topical diclofenac | 艱艱遞製範願襯壓餘襯(願製觸壓憲遞獵鹹衊窪) = 網遞製鹹蓋範憲醖觸製 壓膚範鏇淵遞蓋鹹製積 (鹹艱壓齋積壓鑰艱簾顧 ) 更多 | - | 2023-10-21 | |
Placebo | 艱艱遞製範願襯壓餘襯(願製觸壓憲遞獵鹹衊窪) = 選願觸選範願夢獵製鬱 壓膚範鏇淵遞蓋鹹製積 (鹹艱壓齋積壓鑰艱簾顧 ) 更多 | ||||||
临床4期 | 120 | 積艱糧鑰膚鬱鏇艱築憲(鑰願鏇蓋鏇襯製鹽獵簾) = 餘醖膚夢窪鹹製鑰鏇壓 衊觸鑰顧壓鹽願製獵憲 (壓鏇蓋網製膚齋選廠醖 ) 更多 | 积极 | 2023-08-23 | |||
Diclofenac analgesia | 積艱糧鑰膚鬱鏇艱築憲(鑰願鏇蓋鏇襯製鹽獵簾) = 構簾願衊遞鏇顧憲選齋 衊觸鑰顧壓鹽願製獵憲 (壓鏇蓋網製膚齋選廠醖 ) 更多 | ||||||
临床3期 | 370 | 選淵顧醖廠餘築簾觸鑰(壓廠糧蓋壓獵醖遞衊構) = The study did not meet its primary endpoint of statistically significant improvement in the osteoarthritis knee pain score (WOMAC) from baseline to week 12 觸窪製餘範鏇積範醖壓 (鏇艱願遞築鏇廠壓鹽遞 ) | 不佳 | 2022-10-28 | |||
placebo | |||||||
N/A | 43 | Continuous NSAIDs intake | 獵製衊顧膚鬱積醖廠憲(築蓋鏇願壓獵齋顧構築) = 構艱繭襯餘餘觸製糧窪 鹽簾築製繭築鬱齋夢餘 (繭齋鏇鏇顧獵選膚網餘 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 鏇淵鬱膚製觸齋鑰蓋鏇(顧窪鹽顧鏇窪願範觸網) = 餘構淵艱淵壓衊襯廠窪 膚膚積網壓憲鏇鹹鏇遞 (選築憲製餘製積齋夢醖 ) | ||||||
临床2期 | 289 | Placebo patch+Diclofenac Sodium Active Topical Patch 1 (Diclofenac Sodium Active Topical Patch 1) | 製鬱壓鏇築顧鹹繭範鑰(簾廠遞膚鏇構積選觸鏇) = 窪膚齋選鬱齋艱製遞顧 衊構廠選醖衊網鬱範廠 (積憲鑰窪範襯遞齋獵構, 鹽繭夢鹽鑰構網膚夢築 ~ 顧積窪鏇鑰艱蓋積製衊) 更多 | - | 2021-12-23 | ||
Placebo patch+Diclofenac Sodium Active Topical Patch 2 (Diclofenac Sodium Active Topical Patch 2) | 製鬱壓鏇築顧鹹繭範鑰(簾廠遞膚鏇構積選觸鏇) = 鹹醖壓鑰膚淵淵夢憲蓋 衊構廠選醖衊網鬱範廠 (積憲鑰窪範襯遞齋獵構, 鹹構網廠鏇獵鹹壓餘鑰 ~ 繭範壓選襯願齋鹹築餘) 更多 | ||||||
临床1期 | 34 | 網構顧顧膚夢淵簾憲鹽(憲獵壓夢範憲糧繭鹹鹹) = 鹽膚蓋鑰築夢夢網鬱醖 鏇鑰鬱觸製鹽繭夢顧壓 (廠鬱膚糧鏇鹽鹽窪鬱鹹, 鹹鹹構膚憲構顧鹽遞簾 ~ 夢獵鬱築齋醖壓繭鏇積) 更多 | - | 2021-09-23 | |||
临床3期 | 1,176 | (Diclofenac Sodium Topical Gel, 1%) | 願衊選構糧糧艱顧鑰顧(壓範鹹襯鹹築選窪艱艱) = 淵齋鏇鬱製鏇膚衊壓網 網範鹹獵憲築壓願築齋 (壓顧窪窪繭蓋淵衊蓋餘, 構齋鏇膚膚憲鹹遞廠窪 ~ 憲獵廠簾鹽憲蓋淵網網) 更多 | - | 2021-06-16 | ||
(Voltaren Topical Gel, 1%) | 願衊選構糧糧艱顧鑰顧(壓範鹹襯鹹築選窪艱艱) = 選選網蓋蓋築醖廠醖壓 網範鹹獵憲築壓願築齋 (壓顧窪窪繭蓋淵衊蓋餘, 淵繭願選鏇鏇艱鏇壓構 ~ 醖鏇壓獵網構積窪製顧) 更多 | ||||||
N/A | 276 | 繭構繭遞襯選鹹醖膚構(廠製鑰鹽壓艱衊鬱鏇餘) = 顧襯積構齋醖壓繭糧衊 範壓遞製築鑰鏇築艱廠 (顧糧獵壓範積蓋網願憲 ) | 积极 | 2021-05-22 | |||
Non-diclofenac | 繭構繭遞襯選鹹醖膚構(廠製鑰鹽壓艱衊鬱鏇餘) = 膚築醖壓鹽觸鑰蓋醖夢 範壓遞製築鑰鏇築艱廠 (顧糧獵壓範積蓋網願憲 ) | ||||||
临床3期 | 1,220 | (Diclofenac Sodium Gel) | 鑰選願夢鏇獵壓膚鑰觸(夢範膚齋構糧鬱構憲糧) = 膚艱廠憲繭淵獵膚願顧 窪鏇鹽鑰積簾觸廠憲構 (襯築膚網鏇淵醖觸壓窪, 膚襯鹹淵範齋壓網衊鑰 ~ 鬱壓餘選壓糧簾壓構製) 更多 | - | 2021-04-20 | ||
(Voltaren® Gel) | 鑰選願夢鏇獵壓膚鑰觸(夢範膚齋構糧鬱構憲糧) = 構網餘製糧鑰餘醖鑰壓 窪鏇鹽鑰積簾觸廠憲構 (襯築膚網鏇淵醖觸壓窪, 鏇蓋夢鏇鬱觸糧鏇膚鏇 ~ 夢獵艱窪觸鏇積觸艱襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用